Instituto Universitario de Investigación en Neuroquímica
Centro/Instituto
![Foto de Instituto Universitario de Investigación en Neuroquímica](/img/uploaded/210288F0EBF11B5B400384EE1F7A6332.jpg)
![Foto de Hospital Vall d'Hebron](/img/noimage_org.png)
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (18)
2024
2023
-
APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke
Frontiers in Neurology, Vol. 14
-
Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial
JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788
-
miR-203 drives breast cancer cell differentiation
Breast Cancer Research, Vol. 25, Núm. 1
2022
-
Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation
Journal of experimental & clinical cancer research : CR, Vol. 41, Núm. 1, pp. 285
2021
-
Defining a Target Population to Effectively Test a Neuroprotective Drug
Stroke, Vol. 52, Núm. 2, pp. 505-510
-
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells
Autophagy, Vol. 17, Núm. 6, pp. 1349-1366
2019
-
Therapeutic targeting of HER2–CB 2 R heteromers in HER2-positive breast cancer
Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 9, pp. 3863-3872
-
CIBERSAM: Ten years of collaborative translational research in mental disorders
Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 1, pp. 1-8
-
Erratum: Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (3863–3872) DOI: 10.1073/pnas.1815034116)
Proceedings of the National Academy of Sciences of the United States of America
2016
-
The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
Clinical Cancer Research, Vol. 22, Núm. 10, pp. 2508-2519
2015
-
Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes
Cancer Cell, Vol. 28, Núm. 2, pp. 170-182
2012
-
Guidelines for the use and interpretation of assays for monitoring autophagy
Autophagy, Vol. 8, Núm. 4, pp. 445-544
2011
-
Glaucoma patients present increased levels of diadenosine tetraphosphate, Ap4A, in the aqueous humour
Experimental Eye Research, Vol. 92, Núm. 3, pp. 221-226
-
Implication of the toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis
Annals of Neurology, Vol. 70, Núm. 4, pp. 634-645
2009
-
Plasma levels of 15d-PGJ2 are not altered in multiple sclerosis
European Journal of Neurology, Vol. 16, Núm. 11, pp. 1197-1201
2006
-
TNF-α converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis
Journal of Neurology, Vol. 253, Núm. 6, pp. 701-706
2003
-
Revisión de consenso. Neuroprotección farmacológica en la isquemia cerebral: ¿Es todavía una opción terapéutica?
Neurologia, Vol. 18, Núm. 7, pp. 368-384